Department of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.
Dalian Medical University, Dalian, People's Republic of China.
Int J Nanomedicine. 2024 Oct 19;19:10623-10637. doi: 10.2147/IJN.S480095. eCollection 2024.
Epigenetic dysregulation can significantly trigger the onset and progression of various diseases, epigenetic therapy is a new treatment strategy by changing DNA methylation, histone modification, N6-methyladenosine, chromatin modification and other epigenetic modifications to regulate gene expression levels for therapeutic purposes. However, small-molecule epigenetic drugs face challenges in disease treatment, such as lack of selectivity, limited therapeutic efficacy, and insufficient safety. Nanomedicine delivery systems offer significant advantages in addressing these issues by enhancing drug targeting, improving bioavailability, and reducing nonspecific distribution. This help minimize side effects while increasing both therapeutic effectiveness and safety of epigenetic drugs. In this review, we focus on the mechanism and role of epigenetic regulatory factors in diseases, as well as the challenges faced by small molecule inhibitors in treatment strategies, especially the research advancements in epigenetic drug delivery systems, review and discuss the therapeutic potential and challenges of using nanotechnology to develop epigenetic drug delivery systems.
表观遗传失调可显著引发多种疾病的发生和进展,表观遗传治疗是一种新的治疗策略,通过改变 DNA 甲基化、组蛋白修饰、N6-甲基腺苷、染色质修饰等表观遗传修饰来调节基因表达水平以达到治疗目的。然而,小分子表观遗传药物在疾病治疗中面临挑战,如缺乏选择性、有限的治疗效果和不足的安全性。纳米医学递送系统通过增强药物靶向性、提高生物利用度和减少非特异性分布,在解决这些问题方面具有显著优势。这有助于将药物的副作用最小化,同时提高表观遗传药物的治疗效果和安全性。在这篇综述中,我们重点关注表观遗传调节因子在疾病中的作用和机制,以及小分子抑制剂在治疗策略中面临的挑战,特别是探讨了纳米技术在开发表观遗传药物递送系统方面的研究进展,评估和讨论了使用纳米技术开发表观遗传药物递送系统的治疗潜力和挑战。